Answers are grounded in this paper and cite their sources.
Dual-AAV prime editing could deliver precise gene correction to the central nervous system, but its therapeutic yield depends on a chain of events co-delivery of both vectors to the same cell, editor reconstitution, editing, and rescue that is usually measured separately in different systems. This study presents DUAL-AAV PRIME-DT, an evidence-constrained digital twin that treats AAV-A/AAV-B co-transduction as an explicit cell-level state and propagates it through the whole therapeutic chain. In a synthetic cohort of 10,000 virtual patients with LRRK2-associated Parkinson disease, mean therapeutic coverage is 1.24% (patient-level 5th\95th percentile, 0.12–3.93%), with joint delivery and editing causing the largest losses. Perfect co-transduction raises mean coverage by 74%, whereas assuming independent vectors changes it by only − 5%. Stress tests, sensitivity analysis, and value-of-information analysis identify delivery, reconstitution, and editing as principal levers and show that a terminal phenotype cannot reveal which step failed. All outputs are synthetic and imply no clinical efficacy; the framework specifies the matched same-cell measurements required to replace synthetic priors and to test its predictions.
No takes yet. Share an insight, caveat, or question.
Faizan Ahmad (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: